Compass Pathways swings to Q1 profit on warrant gains and massive cash influx

Compass Pathways (NASDAQ:CMPS) reported first-quarter net income of $91.2 million, or $0.71 per basic share, a dramatic reversal from the $17.9 million loss recorded in the same period last year.

The surge in profitability was fueled by a $130.9 million non-cash gain related to the fair value adjustment of outstanding warrants, a metric that fluctuates alongside the company's share price.

The company’s cash position saw a nearly fourfold increase during the quarter, rising to $466 million from $149.6 million at the end of 2025.

This capital surge follows a period of strategic financing and disciplined spending as the company advances COMP360, its proprietary psilocybin formulation, through the world’s first Phase 3 program for treatment-resistant depression (TRD).

Operating expenses trended lower as the company reaped the benefits of a late-2024 reorganization.

Research and development expenses fell to $26.5 million, down from $30.9 million a year earlier.

Management attributed the decline to the natural progression of Phase 3 trials toward completion and the termination of earlier-stage discovery programs.

General and administrative costs also dipped to $16.4 million, largely due to lower legal and professional fees compared to the financing-heavy first quarter of 2025.

While the company reported a basic profit, it recorded a diluted net loss per share of $0.30, reflecting the potential impact of convertible securities.

Debt increased slightly to $50.5 million, up from $31.6 million in December, as the company maintains a flexible capital structure ahead of anticipated clinical readouts later this year.